Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Opening Session Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jul
16
Today In Oncology
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite Maintenance Treatment vs 2-Years
Setmelanotide in Patients With Acquired Hypothalamic Obesity
Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC
Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL
Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo